⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6040899 | 0.85 | — | — | |
| SCHEMBL14231351 | 0.83 | CASP2 (0.63) | — | |
| SCHEMBL134099 | 0.83 | ALDH1A1 (0.39) | — | |
| SCHEMBL18519236 | 0.82 | MEN1 (0.61) | — | |
| SCHEMBL8973921 | 0.81 | CASP2 (0.67) | — | |
| SCHEMBL933644 | 0.81 | CASP2 (0.67) | — | |
| SCHEMBL28806490 | 0.81 | CASP2 (0.67) | — | |
| SCHEMBL935157 | 0.81 | CASP2 (0.67) | — | |
| SCHEMBL934477 | 0.81 | CASP2 (0.67) | — | |
| SCHEMBL5501338 | 0.81 | CASP2 (0.67) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12472166-B2 | Inhibition of mycobacterial type VII secretion | STICHTING VUMC (NL) | 2025-11-18 | — | — | US | disclosed |
| EP-4021898-B1 | INHIBITION OF MYCOBACTERIAL TYPE VII SECRETION | Stichting Amsterdam UMC (NL) | 2024-05-29 | — | — | EP | disclosed |
| US-20230321267-A1 | Method And Molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-10-12 | — | — | US | disclosed |
| US-11759526-B2 | Method and molecules | MEDIMMUNE, LLC (US) | 2023-09-19 | — | — | US | disclosed |
| US-20220280487-A1 | INHIBITION OF MYCOBACTERIAL TYPE VII SECRETION | STICHTING VU (NL) | 2022-09-08 | — | — | US | disclosed |
| EP-4021898-A1 | INHIBITION OF MYCOBACTERIAL TYPE VII SECRETION | Stichting VUmc (NL) | 2022-07-06 | — | — | EP | disclosed |
| WO-2021040519-A1 | INHIBITION OF MYCOBACTERIAL TYPE VII SECRETION | STICHTING VUMC (NL) | 2021-03-04 | — | — | WO | disclosed |
| US-9885035-B2 | Method for the synthesis of a bifunctional complex | NUEVOLUTION A/S (DK) | 2018-02-06 | — | — | US | disclosed |
| US-20170218085-A1 | SITE-SPECIFIC LABELING METHODS AND MOLECULES PRODUCED THEREBY | NOVARTIS AG (CH) | 2017-08-03 | — | — | US | disclosed |
| US-20170198283-A1 | TEMPLATED MOLECULES AND METHODS FOR USING SUCH MOLECULES | NUEVOLUTION A/S (DK) | 2017-07-13 | — | — | US | disclosed |
| US-20150011434-A1 | METHOD FOR THE SYNTHESIS OF A BIFUNCTIONAL COMPLEX | NUEVOLUTION A/S (DK) | 2015-01-08 | — | — | US | disclosed |
| EP-2515928-B1 | OXYNTOMODULIN PEPTIDE ANALOGUE | LILLY CO ELI (US) | 2014-06-18 | — | — | EP | disclosed |
| US-20140065171-A1 | Site-Specific Labeling Methods and Molecules Produced Thereby | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2014-03-06 | — | — | US | disclosed |
| US-20130040823-A1 | METHOD FOR THE SYNTHESIS OF A BIFUNCTIONAL COMPLEX | NUEVOLUTION A/S (DK) | 2013-02-14 | — | — | US | disclosed |
| US-20130040823-A1 | METHOD FOR THE SYNTHESIS OF A BIFUNCTIONAL COMPLEX | NUEVOLUTION A/S (DK) | 2013-02-14 | — | — | US | disclosed |
| US-20120225089-A1 | NOVEL CONJUGATES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-09-06 | — | — | US | disclosed |
| US-8206901-B2 | Method for the synthesis of a bifunctional complex | NUEVOLUTION A/S (DK) | 2012-06-26 | — | — | US | disclosed |
| US-8206901-B2 | Method for the synthesis of a bifunctional complex | NUEVOLUTION A/S (DK) | 2012-06-26 | — | — | US | disclosed |
| US-20110150820-A1 | METHODS FOR COVALENTLY ATTACHING A POLYMER TO A METHIONINE RESIDUE IN PROTEINS AND PEPTIDES | INSIGHT BIOPHARMACEUTICALS LTD. (IL) | 2011-06-23 | — | — | US | disclosed |
| US-20080161537-A1 | SELECTIVE RADIOLABELING OF BIOMOLECULES | GENERAL ELECTRIC COMPANY (US) | 2008-07-03 | — | — | US | disclosed |